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Pigmentary mosaicism: a review of original
literature and recommendations for future
handling
Anna Boye Kromann1, Lilian Bomme Ousager2, Inas Kamal Mohammad Ali1, Nurcan Aydemir1 and Anette Bygum1*
Abstract
Background: Pigmentary mosaicism is a term that describes varied patterns of pigmentation in the skin caused by
genetic heterogeneity of the skin cells. In a substantial number of cases, pigmentary mosaicism is observed alongside
extracutaneous abnormalities typically involving the central nervous system and the musculoskeletal system. We have
compiled information on previous cases of pigmentary mosaicism aiming to optimize the handling of patients
with this condition. Our study is based on a database search in PubMed containing papers written in English,
published between January 1985 and April 2017. The search yielded 174 relevant and original articles, detailing
a total number of 651 patients.
Results: Forty-three percent of the patients exhibited hyperpigmentation, 50% exhibited hypopigmentation, and
7% exhibited a combination of hyperpigmentation and hypopigmentation. Fifty-six percent exhibited extracutaneous
manifestations. The presence of extracutaneous manifestations in each subgroup varied: 32% in patients with
hyperpigmentation, 73% in patients with hypopigmentation, and 83% in patients with combined hyperpigmentation
and hypopigmentation. Cytogenetic analyses were performed in 40% of the patients: peripheral blood lymphocytes
were analysed in 48%, skin fibroblasts in 5%, and both analyses were performed in 40%. In the remaining 7% the
analysed cell type was not specified. Forty-two percent of the tested patients exhibited an abnormal karyotype; 84% of
those presented a mosaic state and 16% presented a non-mosaic structural or numerical abnormality. In patients with
extracutaneous manifestations, 43% of the cytogenetically tested patients exhibited an abnormal karyotype. In patients
without extracutaneous manifestations, 32% of the cytogenetically tested patients exhibited an abnormal karyotype.
Conclusion: We recommend a uniform parlance when describing the clinical picture of pigmentary mosaicism. Based
on the results found in this review, we recommend that patients with pigmentary mosaicism undergo physical
examination, highlighting with Wood’s light, and karyotyping from peripheral blood lymphocytes and skin fibroblasts. It is
important that both patients with and without extracutaneous manifestations are tested cytogenetically, as the frequency
of abnormal karyotype in the two groups seems comparable. According to the results only a minor part of patients,
especially those without extracutaneous manifestations, are tested today reflecting a need for change in clinical practice.
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* Correspondence: anette.bygum@rsyd.dk
1Department of Dermatology and Allergy Centre, J.B. Winsløws Vej 4 ,
Entrance 142, 5000 Odense C, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kromann et al. Orphanet Journal of Rare Diseases  (2018) 13:39 
https://doi.org/10.1186/s13023-018-0778-6
Background
Segmental pigmentary disorders have been reported since
the 1960’s, and the idea that they represent genetic mosai-
cism has since then gradually gained acceptance within
dermatology [1–3]. Mosaicism refers to the occurrence
of two or more cell populations with different expres-
sion of one or more genes, although derived from a single
zygote [4].
Two fundamentally different mechanisms divide mosaic
skin disorders into two categories: genomic and epigenetic
mosaicism [5]. The Lyon-effect, naturally occurring in
females, is an example of epigenetic mosaicism, as the
random X-inactivation results in differences in the pheno-
typic expression, even though the genetic makeup in all
cells is identical. By contrast, genomic mosaicism is the
presence of at least two populations of cells, which differ in
the genome. Mosaicism implies the coexistence of a nor-
mal and one or more abnormal components, and opposed
to this, a few individuals with segmental dyspigmentation
have been shown to be chimeric, i.e. consist of cell lines
with different but completely normal genome.
In 1901 the German dermatologist Alfred Blaschko pub-
lished an atlas in which he described the lines of various
linear skin diseases [6]. The nowadays well-known lines of
Blaschko form streaks displaying a V-shape or fountain-
like pattern on the back, an S-shape or whorled pattern
over the lateral aspects of the trunk, and a linear pattern
on the extremities. The lines were not based on anatomic
landmarks, but were derived by mapping onto a doll the
patterns observed in 83 patients with nevoid abnormalities
and 63 patients with acquired linear skin disease. The
pattern in the skin is not related to nerve, blood ves-
sel, or lymphatic vessel distribution, but is believed to
originate from movement of cells during embryonic
life [5, 7]. For heuristic purposes, the Blaschkoid dis-
tribution is divided into two subgroups: pigmentation
in either narrow or broad bands [5]. Apart from these,
five cutaneous patterns in which pigmentary mosai-
cism may manifest are generally accepted. The seven
archetypical patterns are described in the following
(Figs. 1 and 2):
Type 1a: Narrow bands, e.g. observed in hypomelanosis
of Ito.
Type 1b: Broad bands, e.g. observed in McCune Albright
syndrome.
Type 2: Checkerboard pattern (also called flag-like)
characterized by alternating squares of hyperpigmentation
with a sharp midline separation.
Type 3: Phylloid pattern with leaf-like or oblong macules
showing a dorsal and ventral midline separation.
Type 4: Patchy pattern without midline separation, e.g.
observed in cases of giant melanocytic nevi that do not
respect the midline.
Type 5: Lateralization pattern often observed in CHILD
syndrome.
Type 6: Sash-like pattern.
Streaks of hypopigmentation or hyperpigmentation along
the lines of Blaschko have been named hypomelanosis of
Ito (HI) and linear and whorled nevoid hypermelanosis
(LWNH) [2]. Both HI and LWNH encompass heteroge-
neous groups of disorders characterized by conditions with
hypopigmented or hyperpigmented skin respectively [5].
Unfortunately, multiple terms are used to describe condi-
tions with pigmentary mosaicism, and to avoid confusion,
we suggest using the most accurate term, namely, pigmen-
tary mosaicism.
The intent of this literature review was to develop a
summary of the current original literature dealing with
the subject pigmentary mosaicism for the purpose of
optimizing the prospective handling of patients with this
condition.
Methods
The study is a literature review comprising original studies
of patients with pigmentary mosaicism. All papers origi-
nated from a database search on PubMed with the purpose
of identifying all patients with pigmentary mosaicism
reported in the literature since 1985. The database was
searched using the following keywords, either by themselves
or in different combinations: pigmentary mosaicism, mosai-
cism, hypopigmentation, hyperpigmentation, Blaschko, lin-
ear and whorled nevoid hypermelanosis, hypomelanosis of
Ito, incontinentia pigmenti achromians, nevus/naevus
depigmentosus, achromic nevus/naevus, nevus/naevus
achromicus, SegPD, segmental pigmentation disorder,
and cutis tricolor. We applied filters to restrict the results to
articles with the following criteria: full texts based on case
reports or reviews written in English between 01.01.1985
and 01.04.2017. Furthermore, we searched the reference lists
of identified articles for additional sources. In total, this
led to the identification of 419 articles of which 174
were original papers and included a total number of
651 cases of pigmentary mosaicism.
For each patient the following data were registered:
sex, age at publication, age at onset, pigmentation type
(hyperpigmentation, hypopigmentation or combination),
pigmentation pattern, and family history (Additional file 1).
The age at onset was recorded by group-classification
as follows: presentation at birth, within 6 weeks, within
the first year, by the age of 2 years, and after the age of
2 years. Furthermore, available information about extra-
cutaneous manifestations, histopathology, and cytogen-
etic analyses were collected.
P-values were calculated using chi-squared test and
StataCorp.
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Fig. 2 Clinical examples of archetypical patterns of cutaneous mosaicism. (a) Hyperpigmentation following Blaschko lines in narrow bands, (b)
hyperpigmentation following Blaschko lines in broad bands, (c) checkerboard pattern, (d) phylloid hyperpigmentation, (e) giant melanocytic
nevus representing patchy pattern, (f) CHILD-syndrome representing lateralization pattern [95] (Reprinted with permission from © Wiley Periodi-
cals, Inc.), (g) and (h) cutis tricolor of the Ruggieri-Happle type (Kindly provided by M. Ruggieri, Catania, Italy)
Fig. 1 Archetypical patterns of cutaneous mosaicism. (a) Type 1a, (b) type 1b, (c) type 2, (d) type 3, (e) type 4, (f) type 5, (g) type 6 seen from the
front, (h) type 6 seen from the back
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Results
Cases
Among a total of 651 published patients, 349 (54%) were
female and 302 (46%) were male. Two-hundred-and-sev-
enty-eight patients (43%) exhibited hyperpigmentation, 324
(50%) exhibited hypopigmentation, and 48 (7%) exhibited a
combination of hyperpigmentation and hypopigmentation.
Pigmentation type was not classified in 1 patient.
The abnormal skin pigmentation occurred on all parts
of the body. Five-hundred-and-sixteen patients (79%) ex-
hibited a Blaschkoid distribution of the dyspigmentation.
Thirty-six patients (6%) exhibited other patterns: 19
patients exhibited a phylloid pattern (53%), 12 patients
exhibited a patchy pattern (33%), 3 patients exhibited
a checkerboard pattern (8%), and 2 patients exhibited
a sash-like pattern (6%). Two patients exhibited a combin-
ation of Blaschkoid and phylloid pattern. The distribution
of the dyspigmentation was not reported in 101 patients
(15%).
Age at onset of the abnormal pigmentation was reported
in 378 patients (58%). In 282 patients (75%) the abnormal
pigmentation was noted early (Table 1): 174 at birth, 25
within 6 weeks, and 83 within the first year. Later observa-
tion occurred in 95 patients (25%): Fifty-seven by the age
of 2 years and 38 after the age of 2 years.
A family history of pigmentary mosaicism occurred in
25 patients (4%), while 342 patients (52%) were charac-
terized as sporadic cases. No data on family history were
given in 284 cases (44%).
Extracutaneous manifestations
Extracutaneous manifestations were described in 367
patients (56%). The distribution of extracutaneous manifes-
tations on each subgroup was 89 patients (32%) with hyper-
pigmentation, 238 patients (73%) with hypopigmentation
and 40 patients (83%) with both hyperpigmentation
and hypopigmentation (Table 2). In 1 patient without
extracutaneous manifestations, the pigmentation type was
not reported. Omitting the patient with unreported/un-
known pigmentation type, the difference in the distribu-
tion of extracutaneous manifestations in the three groups
was found to be statistically significant (p < 0.001).
The most frequently reported abnormalities were de-
velopmental delay, skeletal deformities, seizures, dys-
morphic facial features, and psychomotor retardation
(Additional file 2).
Developmental delay was described in 198 patients (54%
of patients with extracutaneous manifestations). Skeletal
deformities including scoliosis, clinodactyly, delayed bone
age, overlapping toes, and split hand malformation were
described in 140 patients (38%). Seizures, epilepsy or ab-
normal EEG were described in 137 patients (37%), and
dysmorphic facial features such as depressed nasal bridge,
hypertelorism, epicanthus, and low set ears were described
in 114 patients (31%). Psychomotor retardation was de-
scribed in 57 patients (16%) (Table 3). In addition to the
abovementioned, a wide range of other abnormalities was
described, including behavioural disturbances, hearing
loss, and defects in heart, kidney, and brain.
Cytogenetic analyses
Cytogenetic analyses were performed in 263 patients (40%).
Peripheral blood lymphocytes were analysed in 127 patients
(48%), skin fibroblasts in 13 patients (5%), both analyses
were performed in 106 patients (40%), and in 17 patients
(7%) the analysed cell type was not specified (Table 4).
An abnormal result of the cytogenetic analysis was found
in 111 patients (42% of tested patients): 93 presented as
mosaics, while 18 had non-mosaic chromosomal abnor-
malities detected.
Table 1 Age at onset for the different pigmentation types in
650 patients with a classified phenotype
Hyperpigmentation Hypopigmentation Hyper- and
hypopigmentation
At birth 51 106 17
Within
6 weeks
12 12 1
6 weeks –
1 year
34 42 7
1 year –
2 years
9 46 2
After the
age of
2 years
15 18 5
NA 157 100 16
Total 278 324 48
Table 2 Distribution of extracutaneous manifestations in
patients with hyperpigmentation, hypopigmentation, or both
With extracutaneous
manifestations
Without
extracutaneous
manifestations
Total
Hyperpigmentation 89 189 278
Hypopigmentation 238 86 324
Hyper- and
hypopigmentation
40 8 48
NA 0 1 1
Total 367 284 651
Table 3 Distribution of the most frequently reported
extracutaneous manifestations in 367 patients (56%)
Developmental delay 198
Skeletal deformities 140
Seizures, epilepsy and/or abnormal EEG 137
Dysmorphic facial features 114
Psychomotor retardation 57
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In 367 patients with extracutaneous manifestations,
karyotyping was performed in 241 (66%), and an abnor-
mal karyotype (mosaic state, structural abnormality or
numerical abnormality) was found in 104 (43%) of those.
In 284 patients without extracutaneous manifestations,
karyotyping was performed in 22 (8%), and an abnormal
karyotype was found in 7 (32%) of those (Table 5, Fig. 3).
No significant difference in the distribution of chromo-
somal abnormalities was detected in patients with and
without extracutaneous manifestations (p = 0.320).
Of the 263 patients who had a cytogenetic analysis per-
formed, an abnormal result was found in 111 patients
(42%). Ninety-three patients (84%) exhibited a mosaic state
(1 monogenic), and the remaining 18 patients (16%) exhib-
ited non-mosaic chromosomal abnormalities; 13 had struc-
tural anomalies [8–17], 4 had numerical anomalies [18–20],
and 1 abnormal karyotype was not described further [21].
The chromosomes involved in pigmentary mosaicism
were the following: 2 [22, 23], 3 [24–26], 4 [27–30], 5
[31, 32], 7 [33–42], 8 [43], 9 [29, 44, 45], 10 [46], 12 [16,
47, 48], 13 [4, 16, 17, 49–57], 14 [30, 54, 58], 15 [59–61],
16 [62], 18 [16, 30, 43, 63–66], 20 [67–71], 22 [43, 72],
and the sex chromosomes [15, 16, 30, 73–80]. Further-
more, mosaic states with translocations between chro-
mosomes 1, 6, 12, 13, 14 and 21 were found [81–83].
Histopathology
Skin biopsies for histopathologic examination were per-
formed in 238 patients (37%). The biopsies showed an
increase of melanin in the hyperpigmented areas and a
decrease of melanin in the hypopigmented areas, com-
pared to normal skin. In addition, routine transmission
electron microscopy (TEM) on the skin biopsies was
performed in 18 patients (Additional file 3).
Discussion
To define the spectrum of pigmentary mosaicism more
accurately and to map the correlation with extracutaneous
manifestations, we retrospectively reviewed literature detail-
ing 651 patients with pigmentary mosaicism. Importantly,
we found that the clinical picture of pigmentary mosaicism
and the medical terms used to describe it are variable. In
the literature, including recent articles, a wide range of
terms, e.g. LWNH, HI, incontinentia pigmenti achromians,
nevus depigmentosus, achromic nevus, and segmental
pigmentation disorder are used, and these multiple terms
foster unnecessary confusion and ambiguity, as they in fact
all describe the same clinically heterogeneous condition.
Therefore, as Happle et al. states, these expressions should
be avoided since they erroneously indicate nosological en-
tities [5]. Adding to further confusion, the definitions of
these terms seem to vary depending on the author. Patients
with coexisting hyper- and hypopigmented skin may be
referred to as cutis tricolor, a term introduced by Happle et
al. [84]. Lipsker et al. suggested the term cutis bicolor in pa-
tients with two shades of colour [73], but as this term does
not indicate the type of pigmentation anomaly, we recom-
mend using the more specific terms hyperpigmentation
and hypopigmentation.
Table 4 Results of cytogenetic analyses (performed in 263 of
651 patients, 40%)
Normal Abnormal Total
Peripheral blood lymphocytes 103 24 127
Skin fibroblasts 5 8 13
Blood lymphocytes and skin fibroblasts 33 73 106
Unknown cell type analysed 11 6 17
Total 152 111 263
Table 5 Chromosomal findings in 367 patients with
extracutaneous manifestations and 284 patients without
extracutaneous manifestations
With extracutaneous
manifestations
Without extracutaneous
manifestations
Total
Genetic mosaic 87 6 93
Non-mosaic 17 1 18
Normal 137 15 152
Analysis not
performed
126 262 388
Total 367 284 651
Fig. 3 Outcome of cytogenetic analysis. (a) The outcome of cytogenetic
analysis performed in 241 patients with extracutaneous manifestations
and (b) the outcome of cytogenetic analysis performed in 22 patients
without extracutaneous manifestations
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It is often difficult or even impossible to determine,
whether the light or the dark skin component is the
pathological part, especially in children [5, 67]. Based on
successful applications in the literature, we recommend
using Wood’s light to highlight the pigmentation anom-
alies [67, 85].
Cases
The gender composition in our study was almost equal:
46% were male and 54% were female. Similar results
have been observed in other studies [86].
Forty-three percent exhibited hyperpigmentation, 50%
exhibited hypopigmentation, and 7% exhibited a combin-
ation of hyper- and hypopigmentation. The low percentage
of patients exhibiting both hyper- and hypopigmentation
was expected, as this requires three pigmentarily different
cell lines, as opposed to only two in patients exhibiting
either hyper- or hypopigmentation.
The distribution of the dyspigmentation was primarily
Blaschkoid (79%) and occurred on all parts of the body.
In practice, the patterns can be difficult to distinguish,
as reported by Hansen et al. [32]. We must keep in mind
that different authors might classify a given pigmenta-
tion pattern differently, and based on this, biased results
are possible. In most cases however, the pigmentation
pattern is clear and the classification is straightforward.
Furthermore, in doubtful cases it was possible to verify
the classification by the clinical photos provided in most
articles.
Our study showed that the abnormal pigmentation
was noted within the first year of life in 282 (75%) of the
patients. However, this percentage might not be accur-
ate, as it can be difficult to determine the exact time of
presentation of the dyspigmentation, e.g. in very light
skinned Caucasians where a hypopigmented anomaly
can go unnoticed in the first years of life. Additionally,
in many studies the dermatologists saw the patients later
in life, where parents reported the age at onset based on
their memory.
Most frequently, pigmentary mosaicism appears spor-
adically, but a family history of the condition was de-
scribed in 4% of the reported cases. A rare case of two
paternal half-brothers with pigmentary mosaicism of the
hyperpigmented type was reported [26]. A chromosomal
mosaicism with a partial duplication of chromosome 3p
was demonstrated in two different tissues from one pa-
tient, whereas the lymphocytes of the other patient did
not show the chromosomal anomaly and therefore no
common cause for the pigmentary mosaicism was found.
A family with LWNH in three successive generations
has also been reported: a 12-year-old girl, the 45-year-
old mother, and the 65-year-old grandmother [19]. Only
chromosome analysis was performed and here again, no
possible common genetic cause was identified.
Extracutaneous manifestations
In this review a strikingly high frequency of extracuta-
neous manifestations (55%) was seen in comparison with
other individual reviews, where extracutaneous manifes-
tations were reported in 0, 8 and 30% of the patients
[87–89]. Our review revealed a presence of extracuta-
neous manifestations in 32% of patients with hyperpig-
mentation, 73% of patients with hypopigmentation, and
83% of patients with combined hyperpigmentation and
hypopigmentation. These results differ from findings in
previous reviews, where hypopigmentation and hyper-
pigmentation are found to be associated with extracuta-
neous manifestations to an equal extent [87, 90].
The most frequently reported extracutaneous anomalies
were skeletal deformities, seizures, mental retardation,
dysmorphic facial features, and developmental delay. Re-
garding these features it is important to bear in mind that
the groups of different anomalies should be considered
heterogeneous collections of disorders indicating numer-
ous different underlying mosaic states, and not distinct
groups of pheno- or genotypes [5].
Cytogenetic analyses
In this review, cytogenetic analysis was performed in
66% (241 patients) of patients with extracutaneous mani-
festations and by comparison in only 8% (22 patients) of
patients without extracutaneous manifestations. Thirty-two
percent of patients without extracutaneous manifestations
and 43% of patients with extracutaneous manifestations
were found to have abnormal karyotypes. On the basis of
the available data, it is not possible to detect significant dif-
ferences in the presence of chromosomal abnormalities in
the two groups (p = 0.320). The remarkable difference in
proportion of cytogenetically tested patients depicts a need
to change daily practice when handling patients with
suspected pigmentary mosaicism. It is also important to
test patients without extracutaneous manifestations, as
the frequency of abnormal karyotype seems comparable
to patients with extracutaneous manifestations. The data
represent procedures performed over a period of more than
30 years, and the relevance of the results to the recent der-
matologic community can therefore be questioned. How-
ever, the tendency to test primarily when extracutaneous
manifestations are observed is also seen in more recent
studies, which confirms the need for standardization of
future handling.
Sixteen percent of the cytogenetically tested patients
exhibited non-mosaic structural or numerical abnormal-
ities, and in most of these cases the detected aberration
does not in itself explain the pigmentary mosaic. How-
ever, in six cases a chromosomal translocation involving
chromosome X was seen, and differences in gene ex-
pression after X-inactivation of either the normal or the
translocated X may explain the pigmentary mosaicism.
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The chromosomes involved in the investigated cases
of pigmentary mosaicism were: 2, 3, 4, 5, 7, 9, 10, 12, 13,
14, 15, 16, 18, 20, 21, 22, and the sex chromosomes. The
wide range of this result confirms the earlier mentioned
and important point, that the etiology of pigmentary
mosaicism is heterogeneous and complex and should
not be considered distinct syndromes despite similarities
in the clinical picture.
Based on the literature review, we recommend that fi-
broblasts obtained from light and dark skin are analysed
as well as peripheral blood lymphocytes. Despite following
this procedure, failure to detect a chromosomal mosaicism
may persist, if the mosaic state is present in neither lym-
phocytes nor fibroblasts. Taibjee et al. studied 10 patients
with pigmentary mosaicism in whom previous karyotyp-
ing was negative, and were only able to show cytogenetic
abnormalities in keratinocytes in 1 of them [67]. Apart
from the abovementioned reason, another explanation
is that the genetic change responsible for the pigmentary
mosaicism cannot be visualized at the chromosomal level,
but may be anything from a point mutation to a copy
number variation too small to detect by standard chromo-
some analysis [91]. Finally, the differences in pigmentation
may be caused by epigenetic mechanisms.
For therapeutic reasons, it is important to differentiate
pigmentary mosaicism from other diagnoses with abnor-
mal pigmentary findings such as incontinentia pigmenti,
McCune-Albright syndrome, vitiligo, neurofibromatosis
Recklinghausen, piebaldism, and tuberous sclerosis. This,
in addition to earlier mentioned reasons, reinforces our
recommendation to perform cytogenetic evaluation of
peripheral blood lymphocytes and skin fibroblasts in all
patients with suspected pigmentary mosaicism. When per-
forming chromosome analysis, a significant number of
metaphases from both normal and affected skin should be
investigated to ensure detection of even small percentages
of abnormal cells and to detect possible cytogenetic varia-
tions between the two differently coloured skin types.
Though more expensive, a contemporary approach is to
perform chromosome micro array analysis on uncultured
cells [4]. When cell culturing is avoided, the selection bias,
which is usually in favour of the normal clone, is mini-
mized [92]. Another strength of this method is the cap-
acity to detect even small deletions or duplications, which
cannot be detected by standard chromosome analysis [93].
On the other hand only abnormal clones of a certain size
(usually above 5–10%) can be detected by chromosome
micro array. The two approaches have different advan-
tages and may be combined to improve the detection rate
of cytogenetic abnormalities in cases of pigmentary mosai-
cism. Finally, next-generation sequencing (NGS) of the
exome or even the genome may be added as the method
of choice in the near future [94], as it gives the ability to
detect monogenic causes even in a mosaic state. When
further improved, the NGS techniques may even re-
place chromosome micro array and banding techniques
for detection of copy number variations and chromo-
somal rearrangements.
Conclusion
The intent of this literature review was to compile informa-
tion on previous cases of pigmentary mosaicism for the
purpose of optimizing the prospective handling of patients
with this condition. We have examined 174 papers present-
ing 651 patients with pigmentary mosaicism, and found
that the terms used when describing the clinical picture of
pigmentary mosaicism are diverse. The many names give a
fallacious impression of different subgroups and to avoid
confusion, we therefore strongly recommend that future
accounts use the terms hyper- and hypopigmentation and
as an umbrella term: pigmentary mosaicism.
We confirmed that extracutaneous manifestations typic-
ally involve the central nervous system and musculoskeletal
systems, and found that the frequency of these manifesta-
tions was higher than reported in the smaller series of cases
included in the review. Furthermore, we found a statistically
significant difference in the distribution of extracutaneous
manifestations in the three pigmentation types. Finally and
essentially, we can conclude that it is important to test both
patients with and without extracutaneous manifestations
cytogenetically, since no statistically significant difference in
frequency of karyotype anomalies in the two groups was
found.
An apparent difference in the proportion of cytogenetic
tests performed in patients with and without extracuta-
neous manifestations poses a need for consensus and
hence changes in the practical handling of patients with
pigmentary mosaicism. Therefore, based on the results of
the literature review, we propose the following guideline
for classification and handling of all patients with sus-
pected pigmentary mosaicism:
1. Physical examination of the skin.
2. Highlight the pigmentation with Wood’s light.
3. Systematic clinical examination.
4. Standard chromosome analysis of a large number of
metaphases or preferable chromosome micro array
of uncultured cells. Exome sequencing may be an
increasingly available alternative.
5. Exclude differential diagnoses.
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